correct

Bloomberg Law

Congress should seize this opportunity to correct the diversity of clinical trials

Recently, Congress missed a crucial opportunity to ensure that new drugs are tested in diverse patient populations. Ahead of its Sept. 30 expiration and despite bipartisan support for policies to improve clinical trial diversity, lawmakers passed a “clean” FDA user fee reauthorization bill stripped of public health provisions. needed to advance a more equitable clinical …

Congress should seize this opportunity to correct the diversity of clinical trials Read More »